{"disease":{"id":"tumour","name":"tumour"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"lanreotide","indication_name":"Thyroid-stimulating hormone secreting pituitary tumour","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Somatuline Depot","generic_name":"LANREOTIDE","company_name":"Ipsen Pharma","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":10,"revenue":"1200","mechanism":"Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone."},{"drug_id":"plerixafor","indication_name":"Solid malignant tumours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"relatlimab-rmbw","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mozobil","indication_name":"Solid malignant tumours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"opdualag","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04529122","title":"A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05227261","title":"Early Detection of Five Common Cancers Using the ctDNA Analysing Test","phase":"","overall_status":"COMPLETED","enrollment_count":9057,"lead_sponsor_name":"Gene Solutions","has_results":false},{"nct_id":"NCT05918666","title":"National Register of Actionable Mutations","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2098,"lead_sponsor_name":"Federation of Italian Cooperative Oncology Groups","has_results":false},{"nct_id":"NCT07403370","title":"Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06087016","title":"Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT06153576","title":"The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures","phase":"","overall_status":"COMPLETED","enrollment_count":1120,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07044336","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06822413","title":"Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06304818","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT04811443","title":"DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Biocad","has_results":false},{"nct_id":"NCT07140601","title":"Environmental Pollutants and Neurological Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06600022","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":441,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06581432","title":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT01998607","title":"Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw","phase":"","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07262957","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06796907","title":"A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01726452","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Cancer Trials Ireland","has_results":false},{"nct_id":"NCT06888830","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06873672","title":"Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07160725","title":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":315,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06725758","title":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":315,"lead_sponsor_name":"Orion Corporation, Orion Pharma","has_results":false},{"nct_id":"NCT06870396","title":"National Study of Adrenal Tumours","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Society for Endocrinology","has_results":false},{"nct_id":"NCT07315542","title":"Diagnostic and Therapeutic Targets in Cartilaginous Tumours","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"St. Anne's University Hospital Brno, Czech Republic","has_results":false},{"nct_id":"NCT04306432","title":"Cognitive Function After Radiation Therapy for Primary Brain Tumours","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT01078662","title":"Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02664389","title":"Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation","phase":"NA","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT01226316","title":"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":285,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07040683","title":"Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":242,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT01578239","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT06783647","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT04814758","title":"DWI in the Diagnosis of Histological Types of Nephroblastoma in Children","phase":"NA","overall_status":"UNKNOWN","enrollment_count":230,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT06795412","title":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Pyxis Oncology, Inc","has_results":false},{"nct_id":"NCT00687622","title":"Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06692491","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University Shenzhen Hospital","has_results":false},{"nct_id":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07492589","title":"Photo-Acoustic and Ultrasonographic Mammoscope","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Franciscus Gasthuis & Vlietland (Hospital)","has_results":false},{"nct_id":"NCT07446855","title":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05776732","title":"Effect of CaviionTM Precaution Medical Adhesive-related Skin Injury in Tumor Patients With PICC Catherizaion","phase":"NA","overall_status":"UNKNOWN","enrollment_count":165,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07185672","title":"PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT05154604","title":"A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06835426","title":"High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Algemeen Ziekenhuis Maria Middelares","has_results":false},{"nct_id":"NCT05464576","title":"Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT01226394","title":"Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus \"in Principle\" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT03615391","title":"Predictive Role and HuR Mechanisms of Regulation in the Brain Tumours","phase":"","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT02879162","title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":true},{"nct_id":"NCT07111546","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT01396408","title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":137,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT04566614","title":"Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies","phase":"","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}